Prognosis of Ulcerative Colitis-Associated Colorectal Carcinoma Compared to Sporadic Colorectal Carcinoma: A Matched Pair Analysis

Annals of Surgical Oncology

Volumn 23, Issue 3, 2016, Pages 870-876

  Leowardi, Christine ^a   Schneider, Marie Luise ^a   Hinz, Ulf ^a   Harnoss, Jonathan M ^a   Tarantino, Ignazio ^a   Lasitschka, Felix ^b   Ulrich, Alexis ^a   Büchler, Markus W ^a   Kadmon, Martina ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; COLORECTAL CARCINOMA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; RISK FACTOR; ULCERATIVE COLITIS; ADENOCARCINOMA, MUCINOUS; CANCER GRADING; CANCER STAGING; CARCINOMA, SIGNET RING CELL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; COMPLICATION; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SECONDARY; STATISTICAL ANALYSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SIGNET RING CELL; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84957847694     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4915-3     Document Type: Article

References (42)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526–35.
2. Jess T, Frisch M, Jorgensen KT, Pedersen BV, Nielsen NM. Increased risk of inflammatory bowel disease in women with endometriosis: a nationwide Danish cohort study. Gut. 2012;61:1279–83.
3. Castano-Milla M, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther. 2014;39:645–59.
4. Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis. 2006;12:205–11.
5. Askling J, Dickman PW, Karlén P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology. 2001;120:1356–62.
6. Heuschen UA, Hinz U, Allemeyer E, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis. Gastroenterology. 2001;120:841–7.
7. Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc. 2002;56:48–54.
8. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451–9.
9. Matsuoka H, Ikeuchi H, Uchino M, et al. Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort. Int J Colorectal Dis. 2013;28:829–34.
10. Watanabe T, Konishi T, Kishimoto J, Kotake K, Muto T, Sugihara K. Ulcerative colitis-associated colorectal cancer shows a poorer survival than sporadic colorectal cancer: a nationwide Japanese study. Inflamm Bowel Dis. 2011;17:802–8.
11. Higashi D, Futami K, Ishibashi Y, et al. Clinical course of colorectal cancer in patients with ulcerative colitis. Anticancer Res. 2011;31:2499–504.
12. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15:2388–94.
13. Nitsche U, Zimmermann A, Spath C, et al. Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg. 2013;258:775–82.
14. Hyngstrom JR, Hu CY, Xing Y, et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19:2814–21.
15. Brentnall TA, Crispin DA, Bronner MP, et al. Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res. 1996;56:1237–40.
16. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.
17. Aarnio M, Mustonen H, Mecklin JP, Jarvinen HJ. Prognosis of colorectal cancer varies in different high-risk conditions. Ann Med. 1998;30:75–80.
18. Jensen AB, Larsen M, Gislum M, et al. Survival after colorectal cancer in patients with ulcerative colitis: a nationwide population-based Danish follow-up study. Am J Gastroenterol. 2006;101:1283–7.
19. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV Jr. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4:335–42.
20. Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn’s and ulcerative colitis based on three decades of experience. Ann Surg. 2010;252:330–5.
21. Shu X, Ji J, Sundquist J, Sundquist K, Hemminki K. Survival in cancer patients hospitalized for inflammatory bowel disease in Sweden. Inflamm Bowel Dis. 2011;17:816–22.
22. Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br J Cancer. 2009;101:1671–5.
23. Renz BW, Thasler WE, Preissler G, et al. Clinical outcome of IBD-associated versus sporadic colorectal cancer: a matched-pair analysis. J Gastrointest Surg. 2013;17:981–90.
24. Lavery IC, Chiulli RA, Jagelamn DG, Fazio VW, Weakly FL. Survival with carcinoma arising in mucosal ulcerative colitis. Ann Surg. 1982;195:508–12.
25. Gyde SN, Prior P, Thompson H, Waterhouse JA, Allan RN. Survival of patients with colorectal cancer complicating ulcerative colitis. Gut. 1984;25:228–31.
26. Ohman U. Colorectal carcinoma in patients with ulcerative colitis. Am J Surg. 1982;144:344–9.
27. Shaukat A, Salfiti NI, Virnig DJ, et al. Is ulcerative colitis associated with survival among older persons with colorectal cancer in the US? A population-based case–control study. Dig Dis Sci. 2012;57:1647–51.
28. R. K.-I. Zentrum für Krebsregisterdaten-Darmkrebs. http://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/Darmkrebs/darmkrebs_node.htmlR.
29. Murphy G, Devesa SS, Cross AJ, Inskip PD, McGlynn KA, Cook MB. Sex disparities in colorectal cancer incidence by anatomic subsite, race and age. Int J Cancer. 2011;128:1668–75.
30. Nguyen SP, Bent S, Chen YH, Terdiman JP. Gender as a risk factor for advanced neoplasia and colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2009;7(676–81):e1–3.
31. Koo JH, Jalaludin B, Wong SK, Kneebone A, Connor SJ, Leong RW. Improved survival in young women with colorectal cancer. Am J Gastroenterol. 2008;103:1488–95.
32. Chao A, Connell CJ, Cokkinides V, Jacobs EJ, Calle EE, Thun MJ. Underuse of screening sigmoidoscopy and colonoscopy in a large cohort of US adults. Am J Public Health. 2004;94:1775–81.
33. Sinicrope PS, Goode EL, Limburg PJ, et al. A population-based study of prevalence and adherence trends in average risk colorectal cancer screening, 1997 to 2008. Cancer Epidemiol Biomarkers Prev. 2012;21:347–50.
34. Hannaford P, Elliott A. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners’ Oral Contraception Study. Contraception. 2005;71:95–8.
35. Solimando R, Bazzoli F, Ricciardiello L. Chemoprevention of colorectal cancer: a role for ursodeoxycholic acid, folate and hormone replacement treatment? Best Pract Res Clin Gastroenterol. 2011;25:555–68.
36. Hildebrand JS, Jacobs EJ, Campbell PT, et al. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev. 2009;18:2835–41.
37. Söderlund S, Granath F, Broström O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697–703.
38. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case–control study. Am J Gastroenterol. 2011;106:319–28.
39. Principi M, Barone M, Pricci M, et al. Ulcerative colitis: from inflammation to cancer. Do estrogen receptors have a role? World J Gastroenterol. 2014;7;20:11496–504.
40. Saleiro D, Murillo G, Benya RV, Bissonnette M, Hart J, Mehta RG. Estrogen receptor-β protects against colitis-associated neoplasia in mice. Int J Cancer. 2012;131:2553–61.
41. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39:1251–8.
42. Kennelly R, Kavanagh DO, Hogan AM, Winter DC. Oestrogen and the colon: potential mechanisms for cancer prevention. Lancet Oncol. 2008;9:385–91.